• 1
    Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult heart transplant report—2005. J Heart Lung Transplant 2005; 24: 945955.
  • 2
    Burke BA, Chavers BM, Gillingham KJ et al. Chronic renal allograft rejection in the first 6 months posttransplant. Transplantation 1995; 60: 14131417.
  • 3
    Cornell LD, Colvin RB. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2005; 14: 229234.
  • 4
    Kuypers DR, Chapman JR, O'Connell PJ et al. Predictors of renal transplant histology at three months. Transplantation 1999; 67: 12221230.
  • 5
    Moreso F, Lopez M, Vallejos A et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001; 1: 8288.
  • 6
    Davenport A, Younie ME, Parsons JE, Klouda PT. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 1994; 9: 13151319.
  • 7
    Jeannet M, Pinn VW, Flax MH et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111117.
  • 8
    Uehara S, Chase CM, Kitchens WH et al. NK cells can trigger allograft vasculopathy: The role of hybrid resistance in solid organ allografts. J Immunol 2005; 175: 34243430.
  • 9
    Wieczorek G, Bigaud M, Menninger K et al. Acute and chronic vascular rejection in nonhuman primate kidney transplantation. Am J Transplant 2006; 6: 12851296.
  • 10
    Smith RN, Kawai T, Boskovic S et al. Chronic antibody mediated rejection of renal allografts: Pathological serological and immunologic features in nonhuman primates. Am J Transplant 2006; 6: 17901798.
  • 11
    Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 51355141.
  • 12
    Russell PS, Chase CM, Colvin RB. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: Lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997; 64: 15311536.
  • 13
    Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol 1994; 144: 260274.
  • 14
    Cantin B, Wen P, Zhu D et al. Transplant coronary artery disease: A novel model independent of cellular alloimmune response. Circulation 2001; 104: 26152619.
  • 15
    Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 28042812.
  • 16
    Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464470.
  • 17
    Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574582.
  • 18
    Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 23712380.
  • 19
    Vongwiwatana A, Gourishankar S, Campbell PM et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4: 124129.
  • 20
    Sijpkens YW, Joosten SA, Wong MC et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 24092418.
  • 21
    Behr TM, Feucht HE, Richter K et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18: 904912.
  • 22
    Rodriguez ER, Skojec DV, Tan CD et al. Antibody-mediated rejection in human cardiac allografts: Evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5: 27782785.
  • 23
    Smith RN, Brousaides N, Grazette L et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 12021210.
  • 24
    Poelzl G, Ullrich R, Huber A et al. Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy. Transpl Int 2005; 18: 313317.
  • 25
    Corry R, Winn H, Russell P. Primary vascularized allografts of hearts in mice. The role of H2-D, H2-K, and non-H2 antigens in rejection. Transplantation 1973; 16: 343354.
  • 26
    Kremmer E, Thierfelder S, Felber E et al. Monoclonal antibodies to complement components without the need of their prior purification. II. Antibodies to mouse C3 and C4. Hybridoma 1990; 9: 309317.
  • 27
    Rotman S, Collins AB, Colvin RB. C4d deposition in allografts: Current concepts and interpretation. Transplant Rev 2005; 19: 6577.
  • 28
    Gigli I, Sorvillo J, Halbwachs-Mecarelli L. Regulation and deregulation of the fluid-phase classical pathway C3 convertase. J Immunol 1985; 135: 440444.
  • 29
    Russell PS, Chase CM, Sykes M et al. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol 2001; 167: 57315740.
  • 30
    Armstrong AT, Strauch AR, Starling RC et al. Morphometric analysis of neointimal formation in murine cardiac allografts. Transplantation 1997; 63: 941947.
  • 31
    Sachs DH, Winn HJ, Russell PS. The immunologic response to xenografts. Recognition of mouse H-2 histocompatibility antigens by the rat. J Immunol 1971; 107: 481492.
  • 32
    Shenton BK, Bal W, Bell AE et al. The value of flow cytometric crossmatch in cardiac transplantation. Transpl Int 1994; 7: S359–S362.
  • 33
    Minami K, Murata K, Lee CY et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006; 6: 923932.
  • 34
    He C, Schenk S, Zhang Q et al. Effects of T cell frequency and graft size on transplant outcome in mice. J Immunol 2004; 172: 240247.
  • 35
    Millrain M, Chandler P, Dazzi F et al. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol 2001; 167: 37563764.
  • 36
    Baldwin WM, 3rd, Samaniego-Picota M, Kasper EK et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894900.
  • 37
    Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 1994; 28: 437444.
  • 38
    Nijmeijer R, Lagrand WK, Lubbers YT et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003; 163: 269275.
  • 39
    Kuraya M, Ming Z, Liu X et al. Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 2005; 209: 689697.
  • 40
    Bhakdi S, Torzewski M, Paprotka K et al. Possible protective role for C-reactive protein in atherogenesis: Complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109: 18701876.
  • 41
    Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: Is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 22322239.
  • 42
    Rahimi S, Qian Z, Layton J et al. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 2004; 4: 326329.
  • 43
    Fuller TC, Winn HJ. Immunochemical and biologic characterization of alloantibody active in immunologic enhancement. Transplant Proc 1973; 5: 585587.
  • 44
    Aretz HT, Colvin RB. Endomyocardial biopsies. An early warning system for chronic transplant arteriopathy. JAMA 1997; 278: 11971198.
  • 45
    Colvin RB. C4d in liver allografts: A sign of antibody-mediated rejection? Am J Transplant 2006; 6: 447448.
  • 46
    Smith JD, Lawson C, Yacoub MH, Rose ML. Activation of NF-kappa B in human endothelial cells induced by monoclonal and allospecific HLA antibodies. Int Immunol 2000; 12: 563571.
  • 47
    Jin YP, Singh RP, Du ZY et al. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin- dependent manner. J Immunol 2002; 168: 54155423.
  • 48
    Coupel S, Leboeuf F, Boulday G et al. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: An alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 2004; 15: 24292439.
  • 49
    Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985992.
  • 50
    Kilgore KS, Schmid E, Shanley TP et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150: 20192031.
  • 51
    Saadi S, Holzknecht RA, Patte CP, Platt JL. Endothelial cell activation by pore-forming structures: Pivotal role for interleukin-1alpha. Circulation 2000; 101: 18671873.
  • 52
    Auchincloss H, Jr., Sachs DH. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433470.
  • 53
    Wasowska BA, Qian Z, Cangello DL et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001; 71: 727736.